Zealand Pharma A/S (OTCMKTS:ZLDPF) Receives Average Recommendation of "Strong Buy" from Analysts

Key Points

• Zealand Pharma A/S has received a consensus recommendation of "Strong Buy" from six analyst firms, with one analyst giving a buy rating and five categorizing it as a strong buy.
• The company's stock opened at $61.06 and has seen a market cap of $4.34 billion, with a 12-month price range between $54.95 and $141.74.
• In its last earnings report, Zealand Pharma A/S posted an EPS of ($0.67), beating estimates by $0.10, but reported revenue of only $1.14 million against expectations of $248.61 million.

Shares of Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) have received an average rating of "Strong Buy" from the six analysts that are presently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a buy recommendation and five have given a strong buy recommendation to the company.

Several research firms have commented on ZLDPF. Wells Fargo & Company upgraded shares of Zealand Pharma A/S to a "strong-buy" rating in a report on Thursday, July 24th. Barclays upgraded Zealand Pharma A/S to a "strong-buy" rating in a research note on Monday, July 7th. Finally, BNP Paribas raised Zealand Pharma A/S to a "strong-buy" rating in a research report on Tuesday, July 1st.

Zealand Pharma A/S Stock Down 10.6%

ZLDPF stock traded down $6.46 during mid-day trading on Friday, hitting $54.60. 450 shares of the company were exchanged, compared to its average volume of 268. The firm has a fifty day simple moving average of $61.99 and a 200 day simple moving average of $75.28. The company has a market capitalization of $3.88 billion, a PE ratio of -21.93 and a beta of 0.68. The company has a current ratio of 25.10, a quick ratio of 25.07 and a debt-to-equity ratio of 0.03. Zealand Pharma A/S has a twelve month low of $54.11 and a twelve month high of $141.74.

Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported ($0.67) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.77) by $0.10. The company had revenue of $1.14 million for the quarter, compared to the consensus estimate of $248.61 million. Zealand Pharma A/S had a negative net margin of 2,127.09% and a negative return on equity of 13.40%. On average, research analysts forecast that Zealand Pharma A/S will post -2.19 earnings per share for the current fiscal year.

About Zealand Pharma A/S

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.